Subtractive Proteomics Analysis Revealed Lipid A-4’phosphatase (lpxF) as a Potential Candidate for Epitope-based Vaccine Design Against Helicobacter pylori Infection

Amidst the surge in the prevalence of resistant H. pylori infections, WHO in 2017 has given a high priority to clarithromycin-resistant H. pylori for research and to develop new antibacterial agents. In this study, the Helicobacter pylori 26695 strain was investigated with extensive computational biology applications to identify novel therapeutic drug targets or vaccine candidates. During the proteomic functional annotation of an organism, it is crucial to determine the function of proteins. The pathogen-specific pathways were found to include only twelve proteins, paving the way further to determine drug or vaccine targets. Lipoprotein A-4’-phosphatase (LpxF) was found to be a novel vaccine target with the highest antigenicity. Having broad-spectrum conservancy with other H. pylori strains. Further, an immunoinformatic approach was used to predict an effective epitope-based vaccine against H. pylori . LpxF protein has been predicted to have linear and conformational B-cell epitopes and cytotoxic T-lymphocyte epitopes. Virtual screening of all the predicted 35 peptides against human TLR2 receptors resulted in identifying the top 5 peptides. Subsequent redocking with exhaustive parameters reported two peptides with docking energy of -6.9 kcal/mol with a good interaction pattern between the peptide-TLR2 complexes. Furthermore, a panel of two potent epitopes has been proposed that could be used to immunize populations against multiple H. pylori infections.